Sergey A. Lyakhov
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Sergey A. Lyakhov has a total of 108 co-authors. Here are the top co-authors by number of shared publications:
- Sergei A. Andronati
National Academy of Sciences of Ukraine
15 shared publications L. A. Litvinova
National Academy of Sciences of Ukraine
13 shared publicationsE. A. Lyakhova
National Academy of Sciences of Ukraine
5 shared publicationsG. A. Khorokhorina
National Academy of Sciences of Ukraine
4 shared publicationsM. N. Lebedyuk
ITSW Research Center
4 shared publications- Nadezhda M. Zholobak
Zabolotny Institute of Microbiology and Virology, National Academy of Sciences of Ukraine, Academika Zabolotnogo Street, 154, 03680 Kyiv, Ukraine
4 shared publications
Latest Publications
- Open Access
Novel c-Jun N-Terminal Kinase (JNK) Inhibitors with an 11H-Indeno[1,2-b]quinoxalin-11-one Scaffold
C-Jun N-terminal kinase (JNK) plays a central role in stress signaling pathways implicated in important pathological processes, including rheumatoid arthritis and ischemia-reperfusion injury. Therefore, inhibition of JNK is of interest for molecular targeted therapy to treat various diseases. We synthesized 13 derivatives of our reported JNK inhibitor 11H-indeno[1,2-b]quinoxalin-11-one oxime and evaluated their binding to the three JNK isoforms and their biological effects. Eight compounds exhibited submicromolar binding affinity for at least one JNK isoform. Most of these compounds also inhibited lipopolysaccharide (LPS)-induced nuclear factor-κB/activating protein 1 (NF-κB/AP-1) activation and interleukin-6 (IL-6) production in human monocytic THP1-Blue cells and human MonoMac-6 cells, respectively. Selected compounds (4f and 4m) also inhibited LPS-induced c-Jun phosphorylation in MonoMac-6 cells, directly confirming JNK inhibition. We conclude that indenoquinoxaline-based oximes can serve as specific small-molecule modulators for mechanistic studies of JNKs, as well as potential leads for the development of anti-inflammatory drugs.
Open AccessNovel c-Jun N-Terminal Kinase (JNK) Inhibitors with an 11H-Indeno[1,2-b]quinoxalin-11-one Scaffold
C-Jun N-terminal kinase (JNK) plays a central role in stress signaling pathways implicated in important pathological processes, including rheumatoid arthritis and ischemia-reperfusion injury. Therefore, inhibition of JNK is of interest for molecular targeted therapy to treat various diseases. We synthesized 13 derivatives of our reported JNK inhibitor 11H-indeno[1,2-b]quinoxalin-11-one oxime and evaluated their binding to the three JNK isoforms and their biological effects. Eight compounds exhibited submicromolar binding affinity for at least one JNK isoform. Most of these compounds also inhibited lipopolysaccharide (LPS)-induced nuclear factor-κB/activating protein 1 (NF-κB/AP-1) activation and interleukin-6 (IL-6) production in human monocytic THP1-Blue cells and human MonoMac-6 cells, respectively. Selected compounds (4f and 4m) also inhibited LPS-induced c-Jun phosphorylation in MonoMac-6 cells, directly confirming JNK inhibition. We conclude that indenoquinoxaline-based oximes can serve as specific small-molecule modulators for mechanistic studies of JNKs, as well as potential leads for the development of anti-inflammatory drugs.
- Open Access
- 11 March 2020
- Published by Odesa I.I. Mechnikov National University in Odesa National University Herald. Chemistry
- Vol. 25 (1(73)) , 65-75
6- AND 7-AMINOMETHYL-11H-INDENO[1,2-b]QUINOXALINE-11-ONES – SYNTHESIS, DNA AFINITY AND TOXICITY
Синтезовані нові похідні інденохіноксаліну – 6-амінометил-11H-індено[1,2-b]хіноксалін-11-они та 7-амінометил-11H-індено[1,2-b]хіноксалін-11-они, показано, що вони є інтеркаляторами ДНК з афінітетом на рівні противірусного агенту та індуктору інтерферону аміксину та в цілому менш токсичні за нього, що зумовлює доцільність їх подальшого дослідження як потенційних противірусних агентів.
- 11 March 2020
- Published by Odesa I.I. Mechnikov National University in Odesa National University Herald. Chemistry
- Vol. 25 (1(73)) , 65-75
Open Access6- AND 7-AMINOMETHYL-11H-INDENO[1,2-b]QUINOXALINE-11-ONES – SYNTHESIS, DNA AFINITY AND TOXICITY
Синтезовані нові похідні інденохіноксаліну – 6-амінометил-11H-індено[1,2-b]хіноксалін-11-они та 7-амінометил-11H-індено[1,2-b]хіноксалін-11-они, показано, що вони є інтеркаляторами ДНК з афінітетом на рівні противірусного агенту та індуктору інтерферону аміксину та в цілому менш токсичні за нього, що зумовлює доцільність їх подальшого дослідження як потенційних противірусних агентів.
- 1 May 2019
- Published by Elsevier in Bioorganic Chemistry
- Vol. 86, 52-60
Aminoalkoxyfluorenones and aminoalkoxybiphenyls: DNA binding modes
- 1 May 2019
- Published by Elsevier in Bioorganic Chemistry
- Vol. 86, 52-60
Aminoalkoxyfluorenones and aminoalkoxybiphenyls: DNA binding modes
- 1 August 2017
- Published by Elsevier in Bioorganic & Medicinal Chemistry Letters
- Vol. 27 (16) , 3915-3919
Virtual screening, synthesis and biological evaluation of DNA intercalating antiviral agents
- 1 August 2017
- Published by Elsevier in Bioorganic & Medicinal Chemistry Letters
- Vol. 27 (16) , 3915-3919
Virtual screening, synthesis and biological evaluation of DNA intercalating antiviral agents
- Open Access
- 26 April 2016
- Published by Odesa I.I. Mechnikov National University in Odesa National University Herald. Chemistry
- Vol. 21 (1(57)) , 59-71
INDENO[1,2,3-DE]PHTHALAZIN-3(2H)-ONE AND ITS ANALOGS – SYNTHESIS AND ANTIINFLAMMATORY PROPERTIES
ІНДЕНО[1,2,3-de]ФТАЛАЗІН-3(2H)-ОН ТА ЙОГО АНАЛОГИ – СИНТЕЗ ТА ПРОТИЗАПАЛЬНІ ВЛАСТИВОСТІ
- 26 April 2016
- Published by Odesa I.I. Mechnikov National University in Odesa National University Herald. Chemistry
- Vol. 21 (1(57)) , 59-71
Open AccessINDENO[1,2,3-DE]PHTHALAZIN-3(2H)-ONE AND ITS ANALOGS – SYNTHESIS AND ANTIINFLAMMATORY PROPERTIES
ІНДЕНО[1,2,3-de]ФТАЛАЗІН-3(2H)-ОН ТА ЙОГО АНАЛОГИ – СИНТЕЗ ТА ПРОТИЗАПАЛЬНІ ВЛАСТИВОСТІ
- 1 June 2015
- Published by Elsevier in The Journal of Pharmacology and Experimental Therapeutics
- Vol. 353 (3) , 505-516
Anti-Inflammatory Effects and Joint Protection in Collagen-Induced Arthritis after Treatment with IQ-1S, a Selective c-Jun N-Terminal Kinase Inhibitor
C-Jun N-terminal kinases (JNKs) participate in many physiologic and pathologic processes, including inflammatory diseases. We recently synthesized the sodium salt of IQ-1S (11H-indeno[1,2-b]quinoxalin-11-one oxime) and demonstrated that it is a high-affinity JNK inhibitor and inhibits murine delayed-type hypersensitivity. Here we show that IQ-1S is highly specific for JNK and that its neutral form is the most abundant species at physiologic pH. Molecular docking of the IQ-1S syn isomer into the JNK1 binding site gave the best pose, which corresponded to the position of cocrystallized JNK inhibitor SP600125 (1,9-pyrazoloanthrone). Evaluation of the therapeutic potential of IQ-1S showed that it inhibited matrix metalloproteinase 1 and 3 gene expression induced by interleukin-1β in human fibroblast-like synoviocytes and significantly attenuated development of murine collagen-induced arthritis (CIA). Treatment with IQ-1S either before or after induction of CIA resulted in decreased clinical scores, and joint sections from IQ-1S–treated CIA mice exhibited only mild signs of inflammation and minimal cartilage loss compared with those from control mice. Collagen II–specific antibody responses were also reduced by IQ-1S treatment. By contrast, the inactive ketone derivative 11H-indeno[1,2-b]quinoxalin-11-one had no effect on CIA clinical scores or collagen II–specific antibody titers. IQ-1S treatment also suppressed proinflammatory cytokine and chemokine levels in joints and lymph node cells. Finally, treatment with IQ-1S increased the number of Foxp3+CD4+CD25+ regulatory T cells in lymph nodes. Thus, IQ-1S can reduce inflammation and cartilage loss associated with CIA and can serve as a small-molecule modulator for mechanistic studies of JNK function in rheumatoid arthritis.
- 1 June 2015
- Published by Elsevier in The Journal of Pharmacology and Experimental Therapeutics
- Vol. 353 (3) , 505-516
Anti-Inflammatory Effects and Joint Protection in Collagen-Induced Arthritis after Treatment with IQ-1S, a Selective c-Jun N-Terminal Kinase Inhibitor
C-Jun N-terminal kinases (JNKs) participate in many physiologic and pathologic processes, including inflammatory diseases. We recently synthesized the sodium salt of IQ-1S (11H-indeno[1,2-b]quinoxalin-11-one oxime) and demonstrated that it is a high-affinity JNK inhibitor and inhibits murine delayed-type hypersensitivity. Here we show that IQ-1S is highly specific for JNK and that its neutral form is the most abundant species at physiologic pH. Molecular docking of the IQ-1S syn isomer into the JNK1 binding site gave the best pose, which corresponded to the position of cocrystallized JNK inhibitor SP600125 (1,9-pyrazoloanthrone). Evaluation of the therapeutic potential of IQ-1S showed that it inhibited matrix metalloproteinase 1 and 3 gene expression induced by interleukin-1β in human fibroblast-like synoviocytes and significantly attenuated development of murine collagen-induced arthritis (CIA). Treatment with IQ-1S either before or after induction of CIA resulted in decreased clinical scores, and joint sections from IQ-1S–treated CIA mice exhibited only mild signs of inflammation and minimal cartilage loss compared with those from control mice. Collagen II–specific antibody responses were also reduced by IQ-1S treatment. By contrast, the inactive ketone derivative 11H-indeno[1,2-b]quinoxalin-11-one had no effect on CIA clinical scores or collagen II–specific antibody titers. IQ-1S treatment also suppressed proinflammatory cytokine and chemokine levels in joints and lymph node cells. Finally, treatment with IQ-1S increased the number of Foxp3+CD4+CD25+ regulatory T cells in lymph nodes. Thus, IQ-1S can reduce inflammation and cartilage loss associated with CIA and can serve as a small-molecule modulator for mechanistic studies of JNK function in rheumatoid arthritis.
- 24 October 2012
- Vol. 74 (4) , 79-86
Dose-dependent IFN-stimulating and immunomodulating properties of 6H-indolo[2,3-B] quinoxaline derivatives.
Two 6H-indoloquinoxaline derivatives were studied in different doses and schemes of application for their INFgamma-inducing potential and ability to effect functional activity of phagocytic cells. Tested compounds were shown to possess comparable or higher activity than reference drug Amixin in analogous doses. One indoloquinoxaline significantly elevated metabolic activity of macrophages and increased their potential for phagocytosis. Application of multiple treatments and higher doses allowed us to reveal differences between studied derivatives that were not obvious in previous in vivo experiment. Capacity of 6H-indoloquinoxalines to induce vast IFN amounts on in vivo level was demonstrated for the first time.
- 24 October 2012
- Vol. 74 (4) , 79-86
Dose-dependent IFN-stimulating and immunomodulating properties of 6H-indolo[2,3-B] quinoxaline derivatives.
Two 6H-indoloquinoxaline derivatives were studied in different doses and schemes of application for their INFgamma-inducing potential and ability to effect functional activity of phagocytic cells. Tested compounds were shown to possess comparable or higher activity than reference drug Amixin in analogous doses. One indoloquinoxaline significantly elevated metabolic activity of macrophages and increased their potential for phagocytosis. Application of multiple treatments and higher doses allowed us to reveal differences between studied derivatives that were not obvious in previous in vivo experiment. Capacity of 6H-indoloquinoxalines to induce vast IFN amounts on in vivo level was demonstrated for the first time.
- 1 May 2012
- Published by Wiley in Journal of Heterocyclic Chemistry
- Vol. 49 (3) , 678-682
Synthesis of 6‐Aminopropyl‐6H‐indolo[2,3‐b]quinoxaline Derivatives
- 1 May 2012
- Published by Wiley in Journal of Heterocyclic Chemistry
- Vol. 49 (3) , 678-682
Synthesis of 6‐Aminopropyl‐6H‐indolo[2,3‐b]quinoxaline Derivatives
- 1 February 2011
- Published by Elsevier in European Journal of Medicinal Chemistry
- Vol. 46 (2) , 794-798
Synthesis and biological activity of 7H-benzo[4,5]indolo[2,3-b]-quinoxaline derivatives
- 1 February 2011
- Published by Elsevier in European Journal of Medicinal Chemistry
- Vol. 46 (2) , 794-798
Synthesis and biological activity of 7H-benzo[4,5]indolo[2,3-b]-quinoxaline derivatives
- 1 March 2010
- Published by Elsevier in European Journal of Medicinal Chemistry
- Vol. 45 (3) , 1237-1243
Synthesis, cytotoxicity, antiviral activity and interferon inducing ability of 6-(2-aminoethyl)-6H-indolo[2,3-b]quinoxalines
- 1 March 2010
- Published by Elsevier in European Journal of Medicinal Chemistry
- Vol. 45 (3) , 1237-1243
Synthesis, cytotoxicity, antiviral activity and interferon inducing ability of 6-(2-aminoethyl)-6H-indolo[2,3-b]quinoxalines